ArticleMicrobial cell factories2022
Construction of cell factory capable of efficiently converting L-tryptophan into 5-hydroxytryptamine.
Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Metabolic engineering of Streptomyces albulus for de novo serotonin production.Microbial cell factories · 2026Article
- Advances in the microbial biosynthesis of ʟ-tryptophan and its derivatives.Biodesign research · 2025Review
- Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition.Chemistry & biodiversity · 2025Review
- Metabolic Engineering of a Serotonin Overproducing Saccharomyces cerevisiae Strain.Microbial biotechnology · 2025Article
- Engineered phenylalanine hydroxylase coupled with an effective cofactor synthesis and regeneration system for high-yield production of 5-hydroxytryptophan.Bioresources and bioprocessing · 2025Article
- Advances in the microbial synthesis of the neurotransmitter serotonin.Applied microbiology and biotechnology · 2023Review
- Correction to: Construction of cell factory capable of efficiently converting L‑tryptophan into 5‑hydroxytryptamine.Microbial cell factories · 2023Article
- Expanding the application of tryptophan: Industrial biomanufacturing of tryptophan derivatives.Frontiers in microbiology · 2023Review
- Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report.Frontiers in psychiatry · 2023Article
- Metabolic engineering of Escherichia coli for efficient production of L-5-hydroxytryptophan from glucose.Microbial cell factories · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundL-Tryptophan (L-Trp) derivatives such as 5-hydroxytryptophan (5-HTP) and 5-hydroxytryptamine (5-HT), N-Acetyl-5-hydroxytryptamine and melatonin are important molecules with pharmaceutical interest. Among, 5-HT is an inhibitory neurotransmitter with proven benefits for treating the symptoms of depression. At present, 5-HT depends on plant extraction and chemical synthesis, which limits its mass production and causes environmental problems. Therefore, it is necessary to develop an efficient, green and sustainable biosynthesis method to produce 5-HT.
resultsHere we propose a one-pot production of 5-HT from L-Trp via two enzyme cascades for the first time. First, a chassis cell that can convert L-Trp into 5-HTP was constructed by heterologous expression of tryptophan hydroxylase from Schistosoma mansoni (SmTPH) and an artificial endogenous tetrahydrobiopterin (BH
conclusionsThis protocol provided an efficient one-pot method for converting. L-Trp into 5-HT production, which opens up possibilities for the practical biosynthesis of natural 5-HT at an industrial scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.